Atopic Dermatitis Places Heavy Burden on Patients

Share this content:
Atopic Dermatitis Places Heavy Burden on Patients
Atopic Dermatitis Places Heavy Burden on Patients

THURSDAY, July 19, 2018 (HealthDay News) -- Atopic dermatitis (AD) dramatically impacts the quality of life of patients, according to a study published online July 16 in the Annals of Allergy, Asthma & Immunology.

Jonathan I. Silverberg, M.D., Ph.D., from Northwestern University in Chicago, and colleagues assessed the patient-burden of AD among 602 U.S. patients.

The researchers found that adults with AD reported higher proportions of having only fair/poor overall health, being somewhat/very dissatisfied with life, having lower weighted mean Short-Form 12 (SF-12) mental and physical health subscores, and having higher Dermatology Life Quality Index (DLQI) scores, compared to adults without AD. There were significant stepwise decreases by AD severity for overall health, life satisfaction, and SF-12 mental health, and increases of DLQI scores, when adjusting for socio-demographics and multiple comorbid health disorders. The most burdensome AD symptoms were itch (54.4 percent), excessive dryness/scaling (19.6 percent), and red/inflamed skin (7.2 percent), which led to limiting lifestyle (51.3 percent), avoidance of social interaction (39.1 percent), and impacted activities (43.3 percent).

"These data support the heavy burden that AD places on patients, particularly moderate and severe AD," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Sanofi Genzyme and Regeneron, both of which sponsored the study.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Moves to Restrict Flavored E-Cig Sales, Ban Menthol Cigarettes

FDA Moves to Restrict Flavored E-Cig Sales, Ban ...

The move stops short of the full ban on e-cigarettes that had been expected

Name-Brand Medications Driving Spike in U.S. Drug Spending

Name-Brand Medications Driving Spike in U.S. Drug Spending

Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta

is free, fast, and customized just for you!




Already a member?

Sign In Now »